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Abstract
Background: Increased mesenchymal–epithelial transition factor gene (c-MET) expression in several human
malignancies is related to increased tumour progression. The aim of the present study is to explore the relationship
between immunohistochemical expression of c-MET in colorectal carcinoma (CRC) and the clinicopathological
characteristics and follow up data, to compare the expression of c-MET in primary CRC and its metastasis in lymph
nodes and to test its validity as independent prognostic factor.
Methods: Hundred and thirty-five archival CRC and nodal metastases samples were collected from King Abdulaziz
University Hospital, Saudi Arabia. Tissue microarrays were constructed and immunohistochemistry was done to
detected c-MET protein expression. Appropriate statistical analysis was performed.
Results: High c-MET immunostaining was significantly associated with tumour size larger than 5 cm (p < 0.003) and
in left colon subsite (p < 0.05). There was no significant correlation between c-MET protein expression and age, sex,
degree of differentiation, tumour invasion, presence of nodal metastasis, lymphovascular invasion, status of surgical
resection margin, or presence of distant metastasis. Furthermore, no association between c-MET protein expression
and disease free survival. High protein expression of c-MET is associated with the incidence of local disease
recurrence (p < 0.012).
Conclusion: c-MET is a new promising target that may help in understanding the pathogenesis of CRC, and to be
used as independent prognostic biomarker to predict local disease recurrence in CRC. Further molecular in vitro and
in vivo studies are required to pursue c-MET as potential molecular marker of metastases and test the possibility of
its incorporation as a new targeted therapeutic target.
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Background
Colorectal carcinoma (CRC) is among the most common
neoplasms affecting the industrialised nations. According to
the Saudi Arabian National Cancer Registry, CRC is ac-
counting for 11.3 % of all newly diagnosed cases in year
2009. This cancer ranked first among male population and
third among female population [1]. The prognosis of colo-
rectal carcinoma is controlled by variable factors which are
classified by the College of American Pathologists [2] into;
biological and clinical factors as tumour stage, grade, and
molecular factors as genetic markers, DNA contents and
markers of angiogenesis and proliferation. According to
UICC-TNM and American Joint Committee on Cancer
classifications [3] tumour extent, lymph node status,
tumour grade, and the assessment of lymphatic and venous
invasion are still the most relevant clinicopathological prog-
nostic factors. However, tumours of the same stage can fol-
low significantly different clinical courses, indicating a
necessity for the identification of novel prognostic fac-
tors, including molecular markers. Therefore, an active
search is going on to find powerful new prognostic and
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predictive molecular markers for identifying high-risk
patients who would benefit from individually tailored
treatment options [4–6].
One of the most promising biological markers in the
pathogenesis of CRC is the proto-oncogenes c-MET (mes-
enchymal–epithelial transition factor gene) which encodes
the tyrosine kinase receptor for hepatocyte growth factor/
scatter factor (HGF/SF). Interaction between HGF and c-
MET plays a key role in cellular proliferation, survival, mi-
gration, and invasion. The HGF/c-MET axis contributes a
critical physiological function in embryogenesis, angiogen-
esis, and wound healing [7, 8]. Under normal conditions
c-MET is expressed in vascular cells, lymphatic endothe-
lial cells and hematopoietic cells. Somatic mutation and
overexpression of c-MET gene has been described in var-
iety of solid organ tumours including carcinoma of lung,
bladder, kidney, thyroid and CRC [7, 9–11]. Over expres-
sion of c-MET in such tumours is claimed to be related to
increased tumour cell motility, invasiveness, and angio-
genesis which may stimulate tumour metastatic ability
and contribute to tumour aggressiveness [12–14].
The aim of the present study is to explore the relation-
ship between immunostaining of c-MET in CRC and the
clinicopathological characteristics and follow up data, to
compare c-MET immunostaining in primary CRC and




The current study involved 135 paraffin blocks retrieved
from patient’s materials in the archives of the Pathology
Department, King Abdulaziz University, Jeddah, Saudi
Arabia covering the period from January 1995 to December
2010. Paraffin blocks were sliced and stained routinely with
haematoxylin and eosin to evaluate histopathological char-
acteristics of the tumours as well as for histological grading
and staging. Clinical parameters of patients were collected
from the patient's medical records and listed in Table 1.
The study was approved by the Research Committee of the
Biomedical Ethics Unit, Faculty of Medicine, King
Abdulaziz University, Jeddah, Saudi Arabia. All patients in-
cluded in this study gave an informed written consent for
utilisation of their material in research and was accepted by
Research Committee of the Biomedical Ethics Unit.
Tissue microarray construction
A tissue microarray (TMA) was constructed from 135 pri-
mary CRC and 49 corresponding lymph nodes showing
tumour metastasis. Two cylindrical cores of 1.5 mm in
diameter were selected from donor paraffin blocks and
arrayed in 6 recipient paraffin blocks using the automated
tissue arrayer (MASTER 3D HISTECH). Normal placenta
tissue was used as control tissue to help orientation of
samples in each TMA block. TMA blocks were sliced into
4-micron meter sections embedded in sialinated slides in
order to be stained by immunohistochemical staining.
Immunohistochemistry of tissue microarray
Immunohistochemical staining of CRC samples were
using antibody to protein c-MET was performed by
avidin biotin procedure following manufacturer's kit in-
structions. The antibody used was a monoclonal mouse
Anti-Human c-MET (Dako Cytomation Norden A/S,
Glostrup, Denmark, dilution 1:100). IHC procedure was
Table 1 Clinicopathological parameters of cases (n = 135)
Parameter Number (%)
Sex Male 67 (49.6 %)
Female 68 (50.4 %)
Grade Well-differentiated 31 (23 %)
Moderately-differentiated 85 (63 %)
Poorly-differentiated 19 (14 %)
Age <60 years 72 (53.3 %)
≥60 years 63 (46.7 %)
Tumour location Right colon 38 (28.1 %)
Left colon 83 (61.5 %)
Rectum 14 (10.4 %)
Tumour size <5 cm 56 (%41.5)
≥5 cm 79 (58.5 %)
Primary tumour T1 3 (2.2 %)
T2 14 (10.4 %)
T3 108 (80 %)
T4 10 (7.4 %)
Nodal metastasis Positive 63 (46.7 %)
Negative 68 (50.3 %)
Cannot be assessed 4 (3 %)
Distant metastasis Positive 40 (29.6 %)
Negative 95 (70.4 %)
Lymphovascular invasion Positive 20 (14.8 %)
Negative 115 (85.2 %)
Margin status Involved 9 (6.7 %)
Free 126 (93.3 %)
Local disease recurrence Recurrence 48 (35.6 %)
No recurrence 87 (64.4 %)
Survival Died of disease 26 (19.3 %)
Alive 89 (65.9 %)
Not available 20 (14.8 %)
T1: Tumour invades submucosa
T2: Tumour invades muscularis propria
T3: Tumour invades through the muscularis propria into the subserosa or into
non-peritonealised pericolic or perirectal tissues
T4: Tumour directly invades other organs or structures, and/or perforates
visceral peritoneum
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carried out using an automatic immunostainer (Ventana
Bench Mark XT, Ventana Inc., Tucson, AZ). In each
analysis, positive controls were used consisting of CRC
samples previously shown to stain with this antibody.
Tris-buffered saline in place of the primary antibody was
used as a negative control.
Interpretation of immunohistochemical staining
c-MET protein positivity appeared as yellow to brown
staining in tumour cell cytoplasm and/or cell membrane.
The immune reaction was evaluated semiquantitavely
according to staining intensity taking into account the
percentage of cells staining at a given intensity, following
the scoring system given by Takeuchi et al. [15] on a
scale from 0 to 3, with grade 0: negative, 1: weak, 2:
moderate, and 3: intense. When dichotomised for statis-
tical risk assessment, negative (−) and weak (+) staining
were defined as low immunostaining, while moderate
(++) and intense (+++) staining were included in high
immunostaining category.
Statistical analysis
Differences between two groups of patients on one vari-
able were tested by using Mann Whitney test while be-
tween three groups of patients by Kruskal Wallis test
was used. Non-parametric chi-square was used to test
variance along one variable. Binary logistic regression
analysis was used to predict lymph noel metastasis, dis-
tant metastasis, surgical resection margins involvement,
lymphovascular invasion, and local disease recurrence in
relation immunoexpression of c-MET. Estimated odds
ratio {exponential (B)}, 95 % confidence interval (CI) for
exp(B). The Kaplan-Meier procedure was used to calcu-
late the disease-free survival probabilities and the Log
Rank test was used to compare the difference between
survivals. Time was calculated from the date of diagnosis
to the appearance of disease relapse (or date last seen
disease-free). Statistical procedures were performed
using SPSS® Release 16.0. Statistical significance was de-
termined at p value of ≤0.05 and was 2-sided.
Results
c-MET immunostaining profiles
In CRC, c-MET protein expression was observed as in
tumour cells, but was negative in inflammatory cells, endo-
thelial cells, smooth muscle cells or fibroblasts. c-MET im-
munostaining positivity was observed as yellow-brown
staining observed in the cytoplasm and cell membrane.
(Fig. 1) Cases with low c-MET protein expression out-
numbered cases showing high c-MET protein expres-
sion; low expression: 87 cases (64.4 %) and high
expression: 48 cases (35.6 %). There was no difference
between c-MET protein expression in primary tumour
and in lymph node metastasis (Table 2).
The relationship between c-MET immunostaining and
clinicopathological features of CRCs
There was no significant correlation between c-MET ex-
pression and age, sex, degree of differentiation, depth of
tumour invasion, tumour stage, presence of nodal metas-
tasis, lymphovascular invasion, status of surgical margins
and presence of nodal distant metastasis. On the other
hand, high c-MET immunostaining was significantly asso-
ciated with tumour sizes larger than 5 cm and in left colon
location (Table 3).
The relationship between c-MET protein expression and
survival outcome
The survival curves for high- and low c-MET groups
were assessed by the Kaplan-Meier method and com-
pared by a log-rank test which showed no association of
c-MET protein expression with disease-free survival
(Log rank = 1.142, and p = 0.285) (Fig. 2). Regression
Fig. 1 Immunohistochemical labelling of c-MET in CRC and nodal
metastasis using anti c-MET antibody. Diaminobenzidine was used as
chromogen and haematoxylin as counterstain. A combined cytoplasmic
and membranous immunostaining is shown in well differentiated CRC
(a), moderately differentiated CRC (b), poorly differentiated CRC (c),
and in lymph node metastasis (d). Original magnification used is 200x






Low expression 87/135 (64.4 %) 46/61 (75.4 %) 0.129**
High expression 48/135 (35.6 %) 15/61 (24.6 %)
p value <0.001* <0.001*
*One sample non-parametric chi-square test
**Mann–Whitney test
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analysis for c-MET immunoexpression revealed that
high protein expression is associated with the incidence
of recurrence and could be an independent predictor of
occurrence of recurrence (Table 4).
Discussion
CRC remains the second leading cause of cancer-related
death worldwide despite recent advances in adjuvant che-
motherapeutic regimens [16]. Recent researches are con-
cerned about better understanding of the pathogenesis
and biological characteristics of CRC aiming at develop-
ment of new targets for therapy. The role of c-MET signal-
ling has not been fully elucidated in CRC. c-MET is
aberrantly activated in many human cancers through
diverse mechanisms, including point mutations, gene
amplification, transcriptional up-regulation, or ligand
autocrine loops.
The present study showed that c-MET protein is con-
comitantly overexpressed in both primary tumours and
in nodal metastasis which is similar other studies find-
ings [17, 18]. The current study demonstrates that high
protein expression of c-MET protein using immunohis-
tochemical technique was demonstrated to be signifi-
cantly associated with large tumour size, and left side
location of the tumour. However, other studies Zeng et
al., [19] and Liu et al., [20] did not find any correlation
between c-MET and tumour site or size [19, 20]. We did
not find any significant correlation between c-MET pro-
tein overexpression and tumour stage, distant metastasis,
or lymph node positivity contrasting results of previous
studies [15, 19, 20]. In Takeuchi et al. study, they found
high c-MET immunostaining was associated with ad-
vanced stages [15]. Although the same scoring system
was used, their sample size was relatively smaller than in
the current study. Zeng et al. observed C-MET gene
amplification in advanced primary tumour stages. Add-
itionally, Liu et al. showed c-MET mRNA and protein
overexpression in primary CRC with high stage and
positive nodal metastasis [20]. The discrepancy from the
present study may be due to smaller number of tumours.
In the current study, there was no association between
c-MET protein overexpression and disease free survival
which is similar to previous report [18]. In another stud-
ies, c-MET immunostaining was found to be associated
with overall survival [17, 21]. This discrepancy may be
attributed to small sample size and using a different im-
munostaining scoring system.
Significant statistical correlation was identified be-
tween c-MET protein overexpression and tumour recur-
rence. This result is comparable to those of Saigusa et al.
[9] that investigated the relation between c-MET protein
expression and distant recurrence following preoperative
chemotherapy in rectal carcinoma and the effect of c-
MET inhibition on tumour cell growth after radiother-
apy. They demonstrated that c-MET protein overexpres-
sion is related to tumour recurrence and is associated
with worse prognosis and suggested that inhibition of
c-MET is a potential new strategy for reduction of dis-
tant recurrence of rectal carcinoma after preoperative
chemotherapy.
In addition to association of c-MET activation with
tumour progression, previous studies demonstrated
that the HGF/c-MET signalling pathway plays a role
in angiogenesis and lymphangiogenesis by promoting
















***Signficantly associated with c-MET overexpression
Fig. 2 Disease free survival curve (Kaplan-Meier Curve) showing the
survival probabilities of low and high immunoexpression groups of
c-MET (log-rank = 1.142, p = 0.285)
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the growth of endothelial cells, increasing the expres-
sion of pro-angiogenic mediators, such as vascular
endothelial growth factor, and suppressing the activity
of thrombospondin 1-a negative regulator of angio-
genesis. Considering the relevant role of c-MET in
angiogenesis, activated c-MET is considered as adju-
vant pro-metastatic gene for many tumour types.
Novel therapeutic strategies, which focus on the sim-
ultaneous blockade of such proto-oncogene, have
been recently proposed to improve the treatment out-
come [22–24].
The limitation of the current study includes including
missing some follow-up data, short survival time in a
number of patients.
Conclusions
In summary, in the present study the association of high
c-MET immunostaining with larger tumours supports in-
volvement of c-MET in tumour progression. On the other
hand, c-MET is a promising target that may help in un-
derstanding the pathogenesis of CRC, and to be used as
independent prognostic biomarker to predict local disease
recurrence in CRC. Further molecular in vitro and in vivo
studies are required to pursue c-MET as potential molecu-
lar marker of metastases and test the possibility of its
incorporation as a new targeted therapeutic target.
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